Anti-Human ErbB2/Her2 Reference Antibody (BSI-001, RUO) (HY286296)

Name: Anti-Human ErbB2/Her2 Reference Antibody (BSI-001, RUO)
Brand: abinScience
SKU: HY286296
Price: 370 USD
Availability: InStock

데이터시트 제품 공유 정보 복사

가격(USD):

사양:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

수량:

문의하기

개요
이미지
참고 문헌
데이터시트
SDS

개요

카탈로그 번호	HY286296
종 반응성	Human
응용 분야	ELISA, Bioactivity: FCM, Functional assay, Research in vivo
숙주 종	Human
클론성	Monoclonal
이소타입	IgG
클론 ID	BSI-001
생물학적 활성	BSI-001 binds strongly to BT-474 and SK-BR-3 cells with overexpressed HER2 [1]. BSI-001 (100 nM, serially diluted; 3-6 days) exerts weak inhibitory effects on the proliferation of HER2-positive cancer cells when used alone, but it exerts potent synergistic anti-proliferative effects in multiple HER2-positive cancer cell lines when combined with Trastuzumab () at a fixed dose ratio of 1:1 [1]. BSI-001 (72 h) potently inhibits the migration of BT-474 cells when combined with Trastuzumab [1]. BSI-001 (100 nM; 72 h) = induces late-stage apoptosis and PARP cleavage in BT-474 cells when combined with Trastuzumab [1]. BSI-001 (100 nM; 3 days) reduces the total HER2 protein level in BT-474 cells and inhibits HER2-mediated downstream signaling pathways (including the phosphorylation of EGFR, HER3, AKT and ERK) when combined with Trastuzumab [1]. . In combination with Trastuzumab, showed substantially enhanced BT-474 cell proliferation inhibition compared to single agents. Showed stronger synergism between 5G9 and trastuzumab. In SK-BR-3, AU-565, and NCI-N87 cells, the combination of 5G9 and trastuzumab reduced cell viability more effectively. Apoptosis Analysis [1] Cell Line: HER2-positive human breast cancer BT-474 cells Concentration: 100 nM Incubation Time: 72 h Result: Resulted in a significantly lower number of viable BT-474 cells and a higher level of late-stage apoptosis combinated with Trastuzumab, compared to the trastuzumab-pertuzumab combination.
타겟	CD340, EC:2.7.10.1, ERBB2, HER2, MLN 19, MLN19, Metastatic lymph node gene 19 protein, NEU, NGL, Proto-oncogene Neu, Proto-oncogene c-ErbB-2, Receptor tyrosine-protein kinase erbB-2, Tyrosine kinase-type cell surface receptor HER2, p185erbB2
내독소 수준	< 10 EU/mg
순도	>95% as determined by SDS-PAGE.
정제	Protein A/G purified from cell culture supernatant.
등록번호	P04626
형태	Liquid
저장 완충액	0.01M PBS pH 7.4. 데이터시트 인쇄본 또는 로트별 COA에 기재된 구체적인 완충액 정보를 참조하세요.
안정성 및 저장	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
대체 이름	BSI-001, BSI001, BSI001
배경	Receptor tyrosine-protein kinase erbB-2 (CD340/ERBB2) is a ~137 kDa protein. Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. CD340 is the therapeutic target of trastuzumab (Herceptin) and trastuzumab deruxtecan (Enhertu).
참고 문헌	1. Ding X, et al. A novel HER2-targeting antibody 5G9 identified by large-scale trastuzumab-based screening exhibits potent synergistic antitumor activity. EBioMedicine. 2020 Oct;60:102996. [HY286296]
참고사항	For research use only. Not suitable for clinical or therapeutic use.